GGrantIndex
← Search

Flow Cytometry

$15,000P30FY2018CANIH

Oregon Health & Science University, Portland OR

Investigators

Linked publications, trials & patents

Paper 39764100Paper 39763867Paper 39605535Paper 39435649Paper 39386578Paper 39375962Trial NCT07434128Trial NCT07278440Trial NCT07089940Trial NCT05705492Trial NCT04247425Trial NCT04172493Trial NCT04104139Trial NCT04061980Trial NCT04005690Trial NCT03961672Trial NCT03960177Trial NCT03699995Trial NCT03677531Trial NCT03649880Trial NCT03626285Trial NCT03613259Trial NCT03544125Trial NCT03479268Trial NCT03418025Trial NCT03406013Trial NCT03361436Trial NCT03347617Trial NCT03325166Trial NCT03280277Trial NCT03270059Trial NCT03261180Trial NCT03234309Trial NCT03135782Trial NCT03097588Trial NCT03028935Trial NCT03010358Trial NCT03009201Trial NCT02890979Trial NCT02869412Trial NCT02857218Trial NCT02779283Trial NCT02736617Trial NCT02522715Trial NCT02504359Trial NCT02503358Trial NCT02501759Trial NCT02498951Trial NCT02427841Trial NCT02359097Trial NCT02355262Trial NCT02312557Trial NCT02228265Trial NCT02100189Trial NCT02099864Trial NCT02092324Trial NCT02070705Trial NCT02050919Trial NCT01913015Trial NCT01748942Trial NCT01689987Trial NCT01649505Trial NCT01635413Trial NCT01620216Trial NCT01532687Trial NCT01498978Trial NCT01441882Trial NCT01422408Trial NCT01253642Trial NCT01031953Trial NCT01005914Trial NCT00983398Trial NCT00978562Trial NCT00900302Trial NCT00900068Trial NCT00900055Trial NCT00899795Trial NCT00899522Trial NCT00843167Trial NCT00822848Trial NCT00764517Trial NCT00722072Trial NCT00691652Trial NCT00662103Trial NCT00660543Trial NCT00659126Trial NCT00627276Trial NCT00516542Trial NCT00482274Trial NCT00425386Trial NCT00324324Trial NCT00303849Trial NCT00293475Trial NCT00253721Trial NCT00253643Trial NCT00238433Trial NCT00227682Trial NCT00103038Trial NCT00075387Patent 9279811

Abstract

FLOW CYTOMETRY SHARED RESOURCE Director: Philip R Streeter, PhD ABSTRACT / PROJECT SUMMARY The Knight Flow Cytometry Shared Resource provides Knight Cancer Institute members with state-of-the-art instrumentation, expertise, and infrastructure that fully support investigator needs for analytical flow cytometry and cell sorting. In the cancer setting, flow cytometry offers investigators a means of studying cells derived from diverse hematologic and solid cancers, non-cancerous cells from the microenvironments in which cancers reside, and cells from non-cancerous regions of the body. Flow cytometry facilitates the investigation of cells either at the population level or at the single cell level. In addition, the integrated use of cell isolation (by flow cytometry; within the Flow Cytometry Shared Resource) and downstream assessment of isolated cells (by proteomics or genomics; within the Proteomics Shared Resource and/or the Integrated Genomics Shared Resource) provides Knight investigators both the structure and technical expertise to facilitate highly complex interdisciplinary studies. The primary areas of focus for the Flow Cytometry Shared Resource staff are customer service/support, continuous improvement of standard flow cytometric technologies, and the introduction/establishment of new technologies or platforms to enable cutting-edge scientific investigation by Knight members. The services and technologies offered thru the Flow Cytometry Shared Resource are broadly supportive of Knight members, with nearly two-thirds of total Flow Cytometry Shared Resource usage by Knight members. Strategic decisions that impact the facility are made by the Knight senior leadership and the Flow Cytometry Shared Resource Advisory Committee. Support and services include: consultations, contributions to grant applications, education, training, data analyses, analytical flow cytometry, and cell sorting. Further, Knight investigators have the option of instrument self-use or operator-assisted use. The successful introduction/establishment of new technologies has allowed the Flow Cytometry Shared Resource to rapidly adapt to the changing needs of Knight members. By way of example, in 2012, a CyTOF instrument was purchased for the Flow Cytometry Shared Resource. The CyTOF, a mass cytometer, incorporates cytometry and mass spectroscopy, allowing investigators the potential to simultaneously analyze up to 34 parameters associated with individual cells. The resource also obtained a Luminex 200, an instrument enabling multiplex measurements of up to 100 analytes in solution. The technologies offered by the Flow Cytometry Shared Resource are having a positive transformative impact on research conducted by many investigators within the Knight. The establishment of new technologies has allowed the Flow Cytometry Shared Resource to have a central role in the research successes of many Knight members. During the next grant cycle, the Flow Cytometry Shared Resource will be expanded and new innovative platform technologies will be introduced to enable the Flow Cytometry Shared Resource staff to continue to meet the long-term needs of Knight members.

View original record on NIH RePORTER →